397 documents

Read All
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
Read More
20:32 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

BeiGene's BTK inhibitor gets U.S. breakthrough designation

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said FDA granted breakthrough therapy designation to zanubrutinib (BGB-3111) to treat second-line mantle cell lymphoma (MCL). BeiGene President and General Manager of China Xiaobing Wu told BioCentury zanubrutinib is the first...
Read More
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
Read More
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Read More
19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
Read More
00:57 , Jan 4, 2019 |  BC Extra  |  Company News

BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across...
Read More
18:36 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Tecentriq improves PFS by 1.7 months in first-line TNBC

Genentech Inc. reported in October additional data from the Phase III IMpassion130 trial to treat triple-negative breast cancer (TNBC) showing that Tecentriq atezolizumab plus Abraxane nab-paclitaxel as first-line treatment increased median progression-free survival (PFS) vs....
Read More
19:56 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

FDA approves Keytruda for first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA approved Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression. The sBLA was under Priority...
Read More
18:31 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Chinese regulators reviewing pair of BeiGene therapies

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said Aug. 31 that China's National Medical Products Administration accepted an NDA for anti-PD-1 mAb tislelizumab (BGB-A317) to treat relapsed or refractory classical Hodgkin lymphoma (cHL). The news follows BeiGene's Aug....
Read More
19:19 , Aug 31, 2018 |  BC Extra  |  Company News

Chinese regulators reviewing pair of BeiGene therapies

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said Friday that China's National Medical Products Administration accepted an NDA for anti-PD-1 mAb tislelizumab (BGB-A317) to treat relapsed or refractory classical Hodgkin lymphoma (cHL). The news follows BeiGene's Aug. 26...
Read More